Advanced Oncology Quiz: Tumor Biology

ErbB2 mutations cause constitutive receptor activation even without ligand binding. This leads to continuous stimulation of downstream pathways such as MAPK and PI3K–AKT. These pathways promote proliferation, inhibit apoptosis, and enhance survival. Persistent signaling doubles mitogenic input compared to regulated receptors. As a result, cancer cells gain growth independence, increased survival advantage, and enhanced tumor progression through sustained intracellular signal amplification.

Ink4A/B proteins inhibit cyclin-dependent kinases CDK4 and CDK6. By blocking CDK4/6, they prevent phosphorylation of Rb protein. Unphosphorylated Rb binds E2F, suppressing transcription of S-phase genes. This halts progression from G1 to S phase. Loss of Ink4A/B removes this checkpoint control, allowing uncontrolled proliferation. Therefore, Ink4A/B functions as a tumor suppressor regulating cell cycle progression.

Smad4 acts as a transcriptional mediator in the TGF-β pathway. Once activated, it forms complexes that enter the nucleus and promote transcription of CDK inhibitors such as p15 and p16. These inhibitors suppress CDK4/6 activity, reinforcing Rb-mediated cell cycle arrest. This mechanism slows proliferation and maintains tissue homeostasis. Loss of Smad4 removes growth inhibitory signaling, contributing to tumor development.

TGF-β receptors phosphorylate receptor-regulated Smads such as Smad3. Phosphorylated Smad3 complexes with Smad4 and translocates to the nucleus. This complex regulates gene transcription controlling cell cycle arrest and differentiation. The pathway suppresses early tumor growth. Disruption prevents proper transcriptional control and permits proliferation. Thus, TGF-β receptor activation directly influences Smad4-mediated tumor suppression signaling.

TGF-β promotes transcription of Ink4A/B genes through Smad-dependent mechanisms. Increased p15 and p16 levels inhibit CDK4/6, preventing Rb phosphorylation. This maintains Rb-E2F repression, halting S-phase entry. By enforcing G1 arrest, TGF-β acts as a tumor suppressor in early carcinogenesis. Loss of responsiveness enables escape from growth inhibition and promotes malignant progression.

Cancer frequently involves loss of tumor suppressors like Ink4 or Rb. Without Rb, E2F remains active, driving DNA synthesis gene transcription. Loss of Ink4 allows unchecked CDK4/6 activity, leading to Rb phosphorylation and cell cycle progression. These combined alterations bypass G1 restriction points. Such dysregulation enables uncontrolled proliferation, a hallmark of cancer biology.

Natural Killer cells recognize stressed or MHC-I deficient cells without prior sensitization. Cancer cells often downregulate MHC-I to evade cytotoxic T cells. NK cells detect this absence and release perforin and granzymes, inducing apoptosis. They provide rapid innate immune surveillance. This early detection limits tumor establishment before adaptive immunity becomes fully engaged.

Rb binds E2F transcription factors in its hypophosphorylated state. This binding blocks transcription of genes required for DNA synthesis, including thymidylate synthase and DNA polymerase. When CDK4/6 phosphorylates Rb, E2F is released, allowing S-phase progression. Thus, Rb acts as a gatekeeper controlling the G1-to-S checkpoint in cell division.

p16 inhibits the Cyclin D–CDK4 complex by binding CDK4. This prevents Rb phosphorylation. When Rb remains hypophosphorylated, it continues to suppress E2F. Consequently, transcription of S-phase genes is blocked. This inhibition enforces cell cycle arrest. Mutation or deletion of p16 removes this brake, contributing to malignant proliferation.

CD8 is expressed on cytotoxic T lymphocytes. These cells recognize antigenic peptides presented on MHC-I molecules. Upon recognition, they release perforin and granzymes, triggering apoptosis via caspase activation. CD8 co-receptor enhances TCR-MHC interaction specificity. Their role is essential in eliminating virus-infected and malignant cells through adaptive immunity.

Cancer immunoediting describes immune system interaction with tumors in three phases: elimination, equilibrium, and escape. Initially, immune cells destroy aberrant cells. Surviving variants enter equilibrium under immune pressure. Eventually, resistant clones escape detection. This dynamic process shapes tumor immunogenicity and progression while balancing immune activation and tolerance.

E2F is a transcription factor activating genes required for DNA replication, including cyclins, DNA polymerases, and nucleotide synthesis enzymes. When released from Rb inhibition, it drives entry into S phase. Its activity ensures coordinated synthesis of replication machinery. Overactivation due to Rb loss promotes uncontrolled cell proliferation in tumors.

DNA damage activates kinases such as ATM and ATR. These phosphorylate p53, preventing its ubiquitin-mediated degradation by MDM2. Stabilized p53 accumulates in the nucleus and activates transcription of p21 and DNA repair genes. If damage is irreparable, it induces apoptosis. This prevents propagation of mutated genomes.

Bax is a proapoptotic member of the Bcl2 family. Upon activation, Bax inserts into mitochondrial membranes, promoting cytochrome c release. Cytochrome c binds Apaf-1, forming the apoptosome, which activates caspase-9. This triggers downstream caspase-3 activation and cellular dismantling. Thus, Bax promotes intrinsic apoptosis.

p53 induces growth arrest through p21, enabling DNA repair mechanisms to correct mutations. If repair fails, it activates proapoptotic genes such as Bax and PUMA. By preventing replication of damaged DNA, p53 maintains genomic stability. Loss of p53 permits mutation accumulation, chromosomal instability, and tumor progression.